Navigation Links
Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
Date:8/17/2010

WALTHAM, Mass., Aug. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will host the Competitive Landscape Seminar Series: Biologics and Biosimilars, a one-day seminar addressing current and future trends in the biologics and biosimilars markets on September 14, 2010. The seminar will include presentations on a range of industry and therapeutic-specific topics, and will help pharmaceutical companies understand market opportunities for biologics and biosimilars.

The seminar will be held in New York, N.Y. on September 14, 2010 and will answer the following questions:

  • Who are the key players in the biologics market and who will see the greatest growth?
  • Which companies are in the best position to produce biosimilars?
  • How quickly will biologics saturate niche markets?
  • What are the current and future prospects for biologics in the emerging markets?
  • How are payers influencing the biologics market in the United States?
  • What opportunities and challenges lie ahead for agents in specific therapeutic areas such as immune and oncology?

  • "Developments in the biologics and biosimilars markets are constantly evolving and present significant opportunities, as well as potential challenges, for pharmaceutical manufacturers," said Decision Resources Chief Operating Officer Jason LaBonte. "This high-value seminar is geared toward both manufacturers already operating in the biologics and biosimilars markets, as well as companies exploring market opportunities in this space. Attendees will leave with an understanding of the current trends in biologics and biosimilars and how these trends will shape future opportunities."

    Presentation topics include:

  • What Opportunity Remains for Emerging and Novel Immune-Targeted Agents in a TNF-Dominated World?
  • Processes and Paradigms: Which Companies Can Actually Produce Biosimilars and How?
  • Monoclonal Antibodies and the Transformation of the Oncology Landscape
  • First-Launch Small Molecule Therapies and Biologic Agents: Challenges and Opportunities Facing Novel Types of Therapies Entering New Markets
  • Moving Beyond the Major Markets: Current and Future Prospects for Biologics in the Emerging Markets

  • For more information about registration and to view the meeting agenda, please visit: http://www.competitivelandscapeseries.com/biologics-and-biosimilars/.

    Media InvitationMembers of the media interested in receiving an invitation to the Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars should contact Lisa Osgood at 781-296-2606 or by e-mail at losgood@hl-isy.com.

    About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

    About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

    All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

    Christopher Comfort781-296-2606

    781-296-2597 losgood@hl-isy.com

    ccomfort@dresources.com
    '/>"/>

    SOURCE Decision Resources
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
    2. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
    3. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
    4. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
    5. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    6. Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
    7. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
    8. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
    9. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
    10. Hologic Announces Decision in Patent Infringement Suit
    11. Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping Unreasonable, Unfair and Discriminatory
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
    (Date:5/24/2016)... LONDON , May 24, 2016   ... primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced ... (1 litre PEG and ascorbate bowel preparation) versus standard 2 litre ...
    (Date:5/24/2016)... LAWRENCEVILLE, N.J. , May 24, 2016 /PRNewswire/ ... an oncology drug development company, today provided an ... Ib dose escalating clinical trial combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  GEN-1 is an IL-12 ...
    Breaking Medicine Technology:
    (Date:5/25/2016)... ... 25, 2016 , ... Afrimesure specializes in providing clients with ... food and HVAC facilities. Their knowledgeable staff also takes care of the installation, ... Afrimesure offers a variety of MadgeTech systems available for sterilization and temperature monitoring, ...
    (Date:5/25/2016)... Mexico (PRWEB) , ... May 25, 2016 , ... Casa ... the restorative properties of precious stones to complement its new wellness suites . ... two floors and feature a plethora of special services and insuite amenities, from a ...
    (Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... The University ... Nursing and Health Professions. She will lead a team of more than 100 full-time ... will begin her role as dean in late August. , Baker comes to USF ...
    (Date:5/25/2016)... ... May 25, 2016 , ... For more than fifty years, we've suffered whiplash as each ... diets to conform to the latest nutritional advice – advice that was supposed to keep ... than 2 in 3 American adults are considered to be overweight and more than 1 ...
    (Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
    Breaking Medicine News(10 mins):